Clinical Trial

The Effect of Dapagliflozin on Patients With Cardiomyopathy

Study acronym: Dapagliflozin

Recruiting Phase 4

Record status

This record was last updated August 22, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.

Summary

This randomized controlled trial evaluates the efficacy and tolerability of early initiation of dapagliflozin in adult patients hospitalized with acute heart failure (AHF). The study aims to assess the effect of dapagliflozin on pulmonary congestion as measured by lung ultrasound (LUS), length of hospital stay, and cardiac and renal biomarkers. A total of 100 patients will be randomized into two groups: one receiving dapagliflozin plus diuretics and the other receiving diuretics alone. Key outcomes include the reduction of extravascular lung water (assessed by B-lines in LUS), improved diuretic response, changes in NT-proBNP, sST2, CA-125, and NGAL levels, and incidence of acute kidney injury. The study will be conducted at the Cardiology and ICU departments at Kasr Al Ainy Hospital, Cairo University

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2025-07-11; most recent amendment 2025-08-17.

Trial Details

NCT Number	NCT07076615
Lead Sponsor	May Mohamed Abdalla Collaborators: Cairo University
Conditions	Acute Decompensated Heart Failure (ADHF)
Enrollment	100 participants
Start Date	2025-08
Primary Completion	2026-05 (estimated)
Study Completion	2026-05 (estimated)
Updated on ClinicalTrials.gov	2025-08-22